American College of Cardiology2d
OPTION: LAAC vs. Oral Anticoagulation in High-Risk Patients Undergoing AFib Ablation
Left atrial appendage closure (LAAC) in patients at moderate to high risk for stroke who were undergoing catheter atrial fibrillation (AFib) ablation resulted in significantly less bleeding compared ...
American College of Cardiology2d
VANISH2: Catheter Ablation vs. AAD as First-Line Strategy
Among patients with ischemic cardiomyopathy and ventricular tachycardia (VT), catheter ablation as a first-line strategy over antiarrhythmic drugs (AAD) was associated with a lower risk of the primary ...
American College of Cardiology2d
BRAIN-AF: Rivaroxaban Did Not Reduce Cognitive Decline, Stroke and TIA in Younger, Low-Risk Patients With AFib
Rivaroxaban did not reduce the incidence of cognitive decline, stroke or transient ischemic attack (TIA) in patients younger than 65 with nonvalvular atrial fibrillation (AFib) and low risk for stroke ...
American College of Cardiology2d
Late-Breaking Science Explores AI and Other Innovations Designed to Improve Heart Health
A late-breaking session at AHA 2024 highlighted new research focusing on "Smart Cardiology" innovations, including artificial intelligence (AI), aimed at improving heart health. In the PHARM-HF A&F ...
American College of Cardiology2d
Study Shows CV Mortality Hitting Harder in Rural America
People who live in rural areas are dying from cardiovascular disease at a much greater rate than those living in urban areas, according to a report presented at AHA 2024 and simultaneously published ...
American College of Cardiology2d
BPROAD: Findings Supporting Intensive BP Control in Patients With Type 2 Diabetes Put Pressure on Standard Treatment
Intensive treatment to control systolic blood pressure (BP) to less than 120 mmHg significantly reduced the incidence of major cardiovascular events in patients over the age of 50 with type 2 diabetes ...
American College of Cardiology2d
Single-Dose Novel Nex-Z May Reduce Serum TTR Levels
A single dose of nexiguran ziclumeran (nex-z) in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) was associated with a substantial reduction in serum transthyretin (TTR) levels, ...
American College of Cardiology2d
SUMMIT: Tirzepatide Improves Outcomes and Quality of Life For Patients With HFpEF and Obesity
In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, ...
American College of Cardiology2d
Blinded Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation - BRAIN-AF
The BRAIN-AF trial failed to show that rivaroxaban prevents cognitive decline, stroke, or TIA among patients with AF. The primary outcome, cognitive decline (defined by a ≥2-point reduction in ...
American College of Cardiology2d
Comparison of Anticoagulation With Left Atrial Appendage Closure After Atrial Fibrillation Ablation - OPTION
The OPTION trial showed that left atrial appendage closure after AF ablation was associated with a lower risk of non–procedure-related major or clinically relevant nonmajor bleeding compared with oral ...
American College of Cardiology2d
Blood Pressure Control Target in Diabetes - BPROAD
The BPROAD trial showed that in patients with type 2 diabetes and hypertension with elevated CV risk, intensive treatment targeting SBP ≤120 mm Hg reduced the incidence of MACE at 5 years compared ...
American College of Cardiology2d
Ventricular Tachycardia Antiarrhythmics or Ablation in Structural Heart Disease 2 - VANISH2
The VANISH2 trial showed that in patients with ischemic cardiomyopathy and VT, first-line therapy with catheter ablation resulted in fewer VT episodes requiring ICD shock or medical intervention ...